DALLAS, July 29, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. (Amex:RNN). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/RNN
RNN has been relatively stable recently. This is evidenced by the width of its Bollinger Bands which are tighter than normal. Additionally, RNN is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
Rexahn Pharmaceuticals Inc. (RNN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. The Company develops therapies that make it possible to regain normalcy for patients suffering from disease. It has three drug candidates in phase 2 clinical trials during the year ended December 31, 2008, and six or more other drug candidates in pre-clinical development. The Company's clinical-stage pipeline products include Archexin, an anti-cancer Akt inhibitor; Serdaxin, an antidepressant and CNS Disorders drug; and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug. RNN's pre-clinical pipeline includes RX-0201-Nano, RX-0047-Nano, Nano-polymer Anticancer Drugs, RX-0183, RX-5902 and RX-3117.
Message Board Search for RNN: http://www.boardcentral.com/boards/RNN
In the report, the analyst notes:
"For the three-month period ended March 31, 2010, RNN recorded revenues of $18,750. RNN recorded the same amounts in the same period of 2009. In all periods, the revenue reflects the recognition of deferred revenue from a collaborative research agreement with Rexgene Biotech Co. Ltd., a minority stockholder.
"RNN recently announced the formation of a scientific advisory board (SAB) in major depressive disorder (MDD). The SAB will actively collaborate with RNN on the clinical development of Serdaxin® for the treatment of MDD. The SAB is chaired by Dr. Michael Thase, professor of psychiatry and chief of the Division of Mood and Anxiety Disorders Treatment and Research Program at the University of Pennsylvania."
To read the entire report visit: http://www.microstockprofit.com/lp/RNN
See what investors are saying about RNN at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.